专题：2025可持续全球领导者大会&首届绿色产业与可持续消费博览会 联影医疗董事、董事会秘书、首席投资官蔡涛出席2025可持续全球领导者大会并主旨演讲。 蔡涛表示，目前联影医疗已有累计超140款产品获证并推向市场，其中57款已经拿到欧洲的CE认证，53 款获得美国FDA认证，公司AI赋能设备获FDA批准产品超20款。联影医疗现在的产品已经遍及全球， 覆盖了近90个国家和地区，诸多用户分布在几个重要的市场，包括北美地区的美国、加拿大，以及欧 洲，都有联影医疗的产品，此外也包括了亚太、以及中东、非洲、拉美等地区。 2025可持续全球领导者大会于10月16日-18日在上海市黄浦区世博园区召开。 责任编辑：张恒星 2025可持续全球领导者大会由世界绿色设计组织（WGDO）与新浪集团联合主办，国际财务报告准则 基金会（IFRS Foundation）北京办公室协办，新浪财经与世界绿色设计组织北京代表处承办，上海市黄 浦区人民政府支持。 申能集团作为大会全球合作伙伴，在"申能集团专场分论坛"上，围绕"全球变革中的上海行动与多元协 同"这一核心议题，热议"打造可持续发展的东方样板"、"解码上海产业升级的可持续动力"、"探索 ...

10月17日收盘，医疗器械 ETF（562600）下跌1.70%。盘面上看，该ETF持仓股透景生命、热景生物、 诺唯赞等逆势走强，分别上涨4.45%、2.80%、2.25%。 消息面，据国家药监局网站消息，2025年9月，国家药监局共批准注册医疗器械产品348个。其中，境内 第三类医疗器械产品276个，进口第三类医疗器械产品34个，进口第二类医疗器械产品36个，港澳台医 疗器械产品2个。 关于医疗器械行业，中信建投认为，过去四年医疗器械板块持续下跌，今年迎来反弹；器械集采政策优 化、设备招标数据持续改善、渠道库存逐步下降等趋势下，医疗器械细分板块有望在下半年到明年陆续 迎来业绩拐点。 医疗器械 ETF（562600）为投资者提供一键把握医疗器械行业成长机遇的便捷工具。该ETF追踪中证全 指医疗器械指数，精心选取 100 支覆盖医疗器械、医疗服务、医疗信息化等核心医疗领域的代表性上市 公司证券作为样本。从行业结构看，该指数医疗器械行业占比高达 89.34%，集中度突出，能精准捕捉 医疗器械领域的发展红利。截至10月10日，医疗器械 ETF（562600）前十大持仓股中，迈瑞医疗、联 影医疗占比合计23.81%。 ...

Core Insights - The Shanghai Biopharmaceutical Innovation Achievements Exhibition showcases the progress made during the "14th Five-Year Plan" period, emphasizing innovation-driven development and reform in the biopharmaceutical sector [1][2]. Group 1: Innovation and Achievements - Shanghai has approved a total of 30 domestic Class 1 innovative drugs and 45 domestic Class 3 innovative medical devices from 2021 to September 2025, demonstrating its leading position in drug and device innovation in China [2]. - The number of overseas licensing transactions (License-out) from Shanghai reached 38 in 2024, accounting for 35% of the national total, with transaction amounts reaching $30.7 billion, representing 47% of the national total [2]. - Shanghai's research output in top-tier journals has increased significantly, with 3 out of 12 papers in the "Best of Cell 2024" list published by Shanghai researchers, and a total of 127 papers published in four major medical journals from 2021 to 2024 [3]. Group 2: Policy and Reform - The exhibition highlights 14 policy regulations and special measures introduced during the "14th Five-Year Plan" to promote high-quality development in the biopharmaceutical sector, covering areas such as drug regulation, medical device innovation, and clinical trials [5]. - New policies, including the "Opinions on Supporting the Full-Chain Innovation Development of the Biopharmaceutical Industry," aim to enhance the policy framework and support for the biopharmaceutical sector [5]. Group 3: Industry Growth and Structure - The biopharmaceutical industry in Shanghai has grown from ¥761.71 billion in 2021 to ¥984.70 billion in 2024, with a compound annual growth rate of 8.94%, and is expected to exceed ¥1 trillion in 2025 [6]. - By the end of 2024, Shanghai had 2,183 biopharmaceutical enterprises, including 675 manufacturing, 569 service, and 939 wholesale enterprises, indicating a robust industry structure [6]. - Major multinational pharmaceutical companies have established headquarters or R&D centers in Shanghai, with 19 out of the top 20 global pharmaceutical and medical device companies present [6]. Group 4: Financial Support and Investment - Shanghai's biopharmaceutical companies have been active in IPOs, with 102 companies listed across A-shares, Hong Kong, and the US, and several more in the pipeline [7]. - The Shanghai State Investment Corporation established a biopharmaceutical industry mother fund with a total scale of ¥22.5 billion to support the development of the biopharmaceutical innovation ecosystem [7].

Core Viewpoint - The article highlights the achievements and developments in Shanghai's biopharmaceutical industry during the "14th Five-Year Plan" period, emphasizing innovation, reform, and the establishment of a comprehensive ecosystem for biopharmaceutical innovation [1][3][9]. Group 1: Innovation Achievements - Shanghai has approved a total of 30 domestic Class 1 innovative drugs and 45 domestic Class 3 innovative medical devices from 2021 to September 2025, showcasing its leading position in drug and device innovation in China [3]. - The number of overseas licensing transactions (License-out) from Shanghai reached 38 in 2024, accounting for 35% of the national total, with a transaction value of $30.7 billion, representing 47% of the national total [3]. - Research output from Shanghai has significantly increased, with 3 out of 12 papers listed in "Best of Cell 2024" published by Shanghai researchers, and the number of papers in top global medical journals rising from 24 in 2021 to 52 in 2024, totaling 127 [4]. Group 2: Policy and Reform - Shanghai has implemented a series of policies aimed at addressing bottlenecks in the biopharmaceutical sector, including 14 policy regulations covering various key areas such as drug regulation, medical device innovation, and commercialization of innovative drugs [8]. - The exhibition highlighted new policies such as the "Opinions on Supporting the Full Chain Innovation Development of the Biopharmaceutical Industry" and the "Action Plan for Promoting the Full Chain Development of High-end Medical Devices" [8]. Group 3: Industry Growth - The biopharmaceutical industry in Shanghai has expanded from 761.7 billion yuan in 2021 to 984.7 billion yuan in 2024, with an average annual growth rate of 8.94%, and is projected to exceed 1 trillion yuan in 2025 [9]. - By the end of 2024, there were 2,183 large-scale biopharmaceutical enterprises in Shanghai, including 675 manufacturing companies and 569 service companies [9]. - Major multinational pharmaceutical companies have established their headquarters or R&D centers in Shanghai, with 19 out of the top 20 global pharmaceutical and medical device companies present [9].

Group 1 - The medical sector experienced volatility, with the largest medical ETF in A-shares (512170) dropping over 2% in the afternoon, with real-time transactions exceeding 490 million yuan [1] - The ETF's latest scale is 25.73 billion yuan, ranking first among similar ETFs [1] - Notable declines were observed in constituent stocks, with Sanbo Brain Science falling over 6%, and other companies like Yingke Medical and Nanwei Medical dropping more than 4% [1] Group 2 - Ping An Securities indicated that the bidding environment for medical devices will remain favorable in 2025, with strong demand for ultrasound, CT, and MRI equipment driven by policy incentives [3] - The pharmaceutical and biotechnology sectors are currently affected by policy disruptions, but the long-term industry trend remains unchanged, with Chinese innovative drug companies gaining global competitiveness [3] - The medical ETF (512170) passively tracks the CSI Medical Index, with its top ten weighted stocks including WuXi AppTec, Mindray Medical, and others [3]

Core Viewpoint - On October 16, 2025, United Imaging Healthcare (688271) closed at 147.66 yuan, down 0.47%, with a turnover rate of 0.51% and a trading volume of 42,100 lots, amounting to 625 million yuan [1] Trading Information Summary - On October 16, the net outflow of main funds was 20.93 million yuan, accounting for 3.35% of the total transaction amount; the net inflow of retail funds was 8.74 million yuan, accounting for 1.4% of the total transaction amount [2] Company Announcement Summary - On October 14, 2025, United Imaging Healthcare held its 24th meeting of the second board of directors, approving the grant of 528,700 restricted stocks to 36 incentive objects at a price of 94.92 yuan per share. The grant price was adjusted to 94.79 yuan per share due to a cash dividend distribution of 1.30 yuan per 10 shares [3][5] - The board's remuneration and assessment committee confirmed that the incentive objects met the qualifications and conditions set forth in relevant laws and regulations, and the grant was approved unanimously by all directors [3][4] - The legal opinion from Shanghai Tongli Law Firm confirmed that the procedures for the restricted stock incentive plan were properly followed, and the adjustments made were in compliance with regulations [4][6] Restricted Stock Incentive Plan Details - The restricted stock incentive plan involves 528,700 shares, with the adjusted grant price set at 94.79 yuan per share. The adjustment was made following the company's semi-annual dividend distribution [5][6] - The incentive objects include 16 domestic employees and 20 foreign employees, with the total grant representing 0.06% of the company's total share capital. No individual incentive object received more than 1% of the total share capital [6][7] - The vesting schedule for the granted shares is divided into three phases: 30% after 12 months, 30% after 24 months, and 40% after 36 months [7]

Core Viewpoint - The stock of United Imaging Healthcare (688271) has shown a slight decline, with significant net outflows from major funds, indicating potential investor caution in the short term [1][2]. Group 1: Stock Performance - As of October 16, 2025, United Imaging Healthcare closed at 147.66 yuan, down 0.47% with a turnover rate of 0.51% and a trading volume of 42,100 hands, resulting in a transaction value of 625 million yuan [1]. - Over the past five days, the stock has experienced fluctuations, with a notable drop of 3.42% on October 14, 2025, and a total net outflow of 209.27 million yuan on October 16, 2025 [2]. Group 2: Fund Flow Analysis - On October 16, 2025, major funds saw a net outflow of 20.93 million yuan, accounting for 3.35% of the total transaction value, while retail investors had a net inflow of 8.74 million yuan, representing 1.4% of the total [1][2]. - The recent trend shows that major funds have been withdrawing, with a cumulative net outflow of 186 million yuan over the past five days [2]. Group 3: Company Financials - United Imaging Healthcare reported a total market capitalization of 121.695 billion yuan, with a net asset value of 20.787 billion yuan and a net profit of 999.8 million yuan for the first half of 2025, reflecting a year-on-year increase of 12.79% in revenue [3]. - The company’s gross margin stands at 47.93%, while the net profit margin is 16.42%, indicating a strong profitability position compared to industry averages [3]. Group 4: Industry Position - In the medical device industry, United Imaging Healthcare ranks second in total market capitalization and third in net profit among 123 companies, showcasing its competitive strength [3]. - The average target price set by 24 institutions over the past 90 days is 171.35 yuan, with 19 buy ratings and 5 hold ratings, suggesting a generally positive outlook from analysts [4].

Core Viewpoint - Union Medical has rapidly developed over the past decade to become a leading enterprise in China's high-end medical imaging equipment sector, focusing on the integration of artificial intelligence technology and intelligent transformation [1] Group 1: Company Overview - Union Medical has established a comprehensive product line covering five major categories: Computed Tomography (CT), Magnetic Resonance (MR), Molecular Imaging (MI), X-ray (XR), and Radiotherapy (RT) [1] - The company is recognized as the leader in China's medical imaging equipment industry, creating a dual-driven strategy of "high-end breakthroughs + solid foundation" [1] Group 2: Market Dynamics - The implementation of large-scale medical equipment procurement policies across various provinces has significantly accelerated domestic substitution [1] - Union Medical's CT, MR, and MI product lines are expanding in overseas markets, achieving penetration in high-end medical equipment markets in North America and Europe, and ranking prominently in the new installation market in India [1] Group 3: Investment Rating - The company has been given a "Buy" rating, reflecting confidence in its market position and growth potential [1]

Investment Rating - Industry investment rating is "Outperform the Market" (expected to outperform the CSI 300 index by more than 5% in the next 6 months) [2][24] Core Insights - The bidding environment for medical equipment remains robust, with strong demand for procurement in county-level medical communities driven by ongoing equipment update policies since 2025 [4][22] - The procurement scale for medical devices has maintained a high level, with notable monthly figures in July, August, and September 2025 being 12.8 billion, 13.1 billion, and 12.7 billion respectively, showing year-on-year growth rates of +21%, +18%, and -21% [4][13] - Major companies are benefiting significantly from the recovery in equipment update bidding, with procurement figures for September showing ultrasound at 1.646 billion (yoy +30%), CT at 1.717 billion (yoy +29%), and MRI at 1.512 billion (yoy +6%) [5][14] Summary by Sections Equipment Bidding Trends - The bidding environment for medical equipment has been consistently high, with a diverse range of procurement preferences emerging, particularly in county-level medical communities [4][9] - The procurement scale for September 2025 indicates a strong recovery, with various equipment categories showing significant year-on-year growth [5][14] Company Performance - Leading domestic companies are aligned with industry trends, with procurement figures for September showing Mindray at 0.924 billion (yoy +6%), United Imaging at 0.804 billion (yoy +18%), and Kaili at 0.163 billion (yoy +67%) [19][22] - The focus on high-end and intelligent medical devices is expected to drive performance for leading domestic enterprises such as Mindray, United Imaging, and Kaili [6][22] Future Outlook - The ongoing equipment update policies are anticipated to positively impact the bidding market, with expectations for a new round of equipment updates to stimulate demand [22] - The approval of the "Implementation Plan for Strengthening Basic Medical and Health Services" by the State Council is expected to enhance the capabilities of grassroots medical institutions, further opening up the market [22]

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing significant growth, with companies transitioning from generic to innovative drug development, and is expected to continue as a key investment theme in the medium to long term [1][2]. Group 1: Market Performance - The three major A-share indices rose collectively in early trading, with the Shanghai Composite Index up 0.1% to 3916.1 points, the Shenzhen Component Index up 0.15%, and the ChiNext Index up 0.69% [1]. - The total trading volume in the Shanghai and Shenzhen markets reached 12,229 billion yuan, a decrease of 576 billion yuan from the previous day, with over 1,200 stocks rising [1]. Group 2: Innovative Drug Sector - The innovative drug concept stocks strengthened again, with various Hong Kong innovative drug ETFs rising over 2% [1]. - The upcoming European Society for Medical Oncology (ESMO) conference in October 2025 is anticipated to showcase new data from innovative drug companies, including domestic firms like Kangfang Biotech and Hengrui Medicine [1]. Group 3: Industry Insights - The Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs significantly opening new growth avenues for companies [1]. - Major traditional pharmaceutical companies like Hengrui Medicine and Hansoh Pharmaceutical have successfully transformed into innovative firms, while emerging companies are rapidly gaining global recognition [1]. - The aging population is driving demand for chronic disease treatments, contributing to the growth of the silver economy [1]. - The healthcare payment system is steadily growing, with the National Healthcare Security Administration promoting the development of commercial insurance [1]. - The rise of AI is expected to introduce new growth logic in the pharmaceutical industry, with a positive outlook for innovative drugs and medical devices [1]. Group 4: Investment Recommendations - The innovative drug sector is projected to maintain high revenue growth and reduce losses, with Q3 expected to continue this trend [2]. - Investment opportunities are suggested in sectors with improving performance, such as CXO, upstream scientific reagents, and medical devices [2].